Agilent acquires Proscia in deal worth up to $270m
Article excerpt
Highlighted: the sentence this signal was extracted from
Agilent has agreed to acquire digital pathology provider Proscia in a deal worth up to $270m to bolster its existing pathology portfolio with more instruments, reagents, and software. Under the all-cash transaction, Agilent will pay $240m up front, with the deal swelling by up to $30m pending future performance milestones being met. Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms. Find out more Agilent highlighted that the acquisition builds on a multi-year global distribution agreement it established with Proscia in March 2023 to offer a digital diagnostic pathology system combining its pathology staining toolkit with Proscia's Concentriq Dx. The digital pathology software platform, which went on to obtain US Food and Drug Administration (FDA) clearance in 2024, allows pathologists to view, interpret, and manage whole slide images within a digital environment. Following its recently completed $950m acquisition of Biocare Medical in June, Agilent asserted that acquiring Proscia will result in various strategic and financial benefits. Most notably, Agilent said the takeover will strengthen its existing position in pathology instrumentation and reagents by combining its diagnostic capabilities with Proscia's Concentriq Dx and the platform's established customer base. Proscia serves more than 4,000...
Keep reading with a free account
The rest of this article, and every signal for Agilent, is in your free account.
